Ituximab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ituximab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ituximab Today - Breaking & Trending Today

ILD Not Increased With MTX in Patients With Dermatomyositis

Treatment with methotrexate was not associated with an increased risk for interstitial lung disease (ILD) in patients with dermatomyositis. ....

New York , United States , Jillt Shah , York University Langone Health , National Institutes , Health Sponsored All , New York University Langone Health , New York City , Biologic Therapy , Interstitial Lung Disease , Alignant Neoplasia , Alignant Neoplasm , Antineoplastic Drug , Nti Cancer Agents , Monoclonal Antibody , Electronic Health Records ,

Combo Therapy Prolongs Survival in Gastric Cancer Patients

The overall survival advantage held regardless of PD-L1 status in patients receiving the first-line combination of cadonilimab and standard chemotherapy. ....

United States , Jiafu Ji , American Association For Cancer Research , Drug Administration , Institute For Cancer Research , University Cancer Hospital , American Association , Cancer Research , Peking University Cancer Hospital , Beijing Institute , New Treatment Paradigm , Advanced Gastric , Noncolorectal Gastrointestinal Cancer , Oncolorectal Gi Cancer , Combination Chemotherapy , Gastric Cancer , Alignant Stomach Neoplasm , Stomach Cancer , Gastric Carcinoma , Alignant Neoplasia , Alignant Neoplasm , Biologic Therapy , Antineoplastic Drug , Nti Cancer Agents ,

Three early-phase clinical studies show promising initial data for patients with lymphoma, gastric cancers

Three early-phase clinical studies presented by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2024 show promising initial data for patients with lymphoma, gastric or gastroesophageal junction cancers, and specific molecularly selected tumors. ....

United States , Klus Pharma , Jordi Rodon , Timothy Yap , Merck Co , Development Agreement , Andrew Sabin Family Fellowship Program , American Association For Cancer Research , University Of Texas Md Anderson Cancer Center , Experimental Therapeutics Clinical Trials Network , Bristol Myers Squibb Company , National Cancer Institute Therapy Evaluation Program , National Cancer Institute , Astrazeneca Pharmaceuticals , National Institutes Of Health , Manderson Cancer , Cancer Center , American Association , Cancer Research , Annual Meeting , Paolo Strati , Lymphoma Society Scholar , Clinical Research Award , Kite Scholar Award , Andrew Sabin Family Fellowship , Investigational Cancer Therapeutics ,

FDA Expands Enhertu Indication to HER2-Positive Solid Tumors

The move from the FDA marks the first tumor-agnostic approval of a HER2-directed therapy and antibody drug conjugate. ....

United States , University Of Texas Md Anderson Cancer Center , Drug Administration , Daiichi Sankyo Inc , Daiichi Sankyo , Cancer Center , Boxed Warning , Breast Cancer , Alignant Breast Neoplasm , Breast Carcinoma , Biologic Therapy , Antineoplastic Drug , Nti Cancer Agents , Noncolorectal Gastrointestinal Cancer , Oncolorectal Gi Cancer , Nt Specialty , Ead And Neck Surgery Ent Speciality ,

First-Line Highly Effective Therapy Better for Pediatric MS

New research supports the use of highly effective therapies as first-line treatment in children with relapsing-remitting pediatric-onset multiple sclerosis. ....

Department Of Pediatric Neurology , University Angers , Expanded Disability Status Scale , Nail Benallegue , Pediatric Neurology , Multiple Sclerosis Ms , S Multiple Sclerosis , Biologic Therapy , Antineoplastic Drug , Nti Cancer Agents , Glatiramer Acetate , Interferon Beta , Fn Beta , Interferon Beta , Monoclonal Antibody ,